Using ketamine in treatment resistant de...

Prof. Klaus Ebmeier is the Foundation Chair of Old Age Psychiatry. In this interview he gives his point of view on dementia, normal aging and why new treatments are not yet effective. He also explains why failure is the bread-and-butter of research and gives valuable advice to fu ... Show More

An interview with Professor Phil Burnet, who discusses his research into the influence of the gut microbiome on brain health. He talks about novel findings, potential future work, and takes questions from trainee psychiatrists and researchers. 

Professor Daniel Freeman discusses his research into how psychosis can be treated through the use of cognitive behavioural techniques Professor Daniel Freeman is interviewed by Daniel Maughan about his current randomised controlled treatment trials. This is a test of a new target ... Show More

One week ago, Matthew Perry’s autopsy report came back, finding that the ‘Friends’ actor died from the acute effects of ketamine overdose. His death has sharpened focus on the popular and controversial drug. Ketamine has been hailed as a miracle cure for depression and anxiety, c ... Show More

Dr. John Krystal, a leading psychiatrist and neuroscientist, explains how ketamine works in the brain, why it’s revolutionizing depression treatment, and what the future holds for psychedelic-assisted therapy. His journey to discovering the revolutionary benefits of Ketamine trea ... Show More

New developments in actor Matthew Perry’s death are shining a light on the ethics and efficacy of using ketamine as a therapeutic drug. To learn more about the promise and pitfalls of ketamine treatment, CNN’s Chief Medical Correspondent Dr. Sanjay Gupta turns to David Feifel, on ... Show More

Show notes at pharmacyjoe.com/episode1026. In this episode, I’ll discuss hallucinations from low-dose ketamine use in the ICU. The post 1026: Is the Low-Dose Ketamine In the Room With Us Right Now? appeared first on Pharmacy Joe. 

It's time to make psychiatry more psychedelic, says psychiatrist Benjamin Lewis. Sharing results from his clinical trial on psychedelic-assisted therapy, he highlights how group therapy paired with the safe use of psilocybin, a compound found in magic mushrooms, has the potential ... Show More

After it was approved in 2019, Spravato, a depression treatment derived from the club drug ketamine, was looking like a dud. But recently it has taken off, and it surpassed $1 billion in annual sales last year for its maker, Johnson and Johnson. Further Listening: -A Lawyer Says ... Show More

Exercise and a better diet, prior to surgery, can improve outcomes. Daniel McIsaac, a professor of anaesthesiology from the University of Ottowa and lead author of that research, joins us to talk about getting those results into practice. Julia Sinclair, professor of addiction ps ... Show More

Can a substance found in magic mushrooms alleviate depression? To discuss this with Pat was Luke O’Neill, Professor of Biochemistry at the School of Immunology, Trinity College . 

What do the clinical trials of psilocybin and other psychedelics show in terms of efficacy and safety? How much of the benefit with psychedelic treatment is attributable to psychological support? Is the psychedelic trip important for the therapeutic benefits of psychedelic treatm ... Show More

Dr. Rae Bacharach discusses the Neurology Today article, "Depression During Intern Year Increases Risk for Persistent MD Depression: What Can Training Programs Do to Intervene?" by Gina Shaw, available in the September 5th issue of Neurology Today or at neurologytoday.com.  Show ... Show More